問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5307Cases

2026-03-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)

  • Condition/Disease

    Alzheimer Disease, Agitation

  • Test Drug

    KarXT/KarX-EC

Participate Sites
5Sites

Recruiting5Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

  • Condition/Disease

    Narcolepsy Type 2

  • Test Drug

    ALKS 2680

Participate Sites
3Sites

Recruiting3Sites

2026-05-01 - 2027-07-28

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  • Condition/Disease

    Narcolepsy Type 1

  • Test Drug

    ALKS 2680

Participate Sites
3Sites

Recruiting3Sites

2026-05-01 - 2030-01-31

Phase II/III

Not yet recruiting
An Open-Label, Single-arm, Multicenter Phase 2/3 Clinical Trial Evaluating Avatrombopag in Adult Patients with Aplastic Anemia (AA) Refractory to or Ineligible for Immunosuppressive Therapy or with Relapsed AA after Immunosuppressive Therapy

  • Condition/Disease

    Aplastic Anemia

  • Test Drug

    Avatrombopag

Participate Sites
4Sites

Recruiting4Sites

2026-05-01 - 2027-12-31

Phase II

Active
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat

  • Condition/Disease

    Subcutaneous Fat

  • Test Drug

    CBL-514

Participate Sites
8Sites

Recruiting8Sites

2026-05-05 - 2029-01-08

Phase III

Active
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)

  • Condition/Disease

    Obesity, Obstructive Sleep Apnoea

  • Test Drug

    NNC0487-0111 B

Participate Sites
4Sites

Not yet recruiting4Sites

2026-05-05 - 2029-02-21

Phase III

Not yet recruiting
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)

  • Condition/Disease

    Obesity, Obstructive Sleep Apnoea

  • Test Drug

    NNC0487-0111 B

Participate Sites
4Sites

Not yet recruiting4Sites

2026-05-11 - 2030-01-07

Phase III

Not yet recruiting
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

  • Condition/Disease

    Heart Failure, Obesity

  • Test Drug

    NNC0487-0111 B

Participate Sites
5Sites

Not yet recruiting5Sites

2025-01-03 - 2028-12-31

Phase III

Active
MAGNITUDE-2: A phase 3, multinational, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of NTLA-2001 in participants with transthyretin amyloid disease (ATTRv-PN), a hereditary polyneuropathy.

  • Condition/Disease

    Transthyretinopathy with hereditary polyneuropathy (ATTRv-PN)

  • Test Drug

    NTLA-2001

Participate Sites
3Sites

Recruiting3Sites

2025-01-06 - 2027-01-04

Phase I

Not yet recruiting
A phase Ib/IIa, open-label, dose-escalation and dose-expansion trial was conducted in patients with advanced or metastatic colorectal cancer to evaluate the safety, tolerability, and preliminary efficacy of HCB101, cetuximab/bevacizumab, and FOLFOX/FOLFIRI in combination.

  • Condition/Disease

    Advanced or metastatic rectal cancer

  • Test Drug

    HCB101

Participate Sites
1Sites

Recruiting1Sites

1 36 37 38 39 40 531
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB